|
Market Closed -
Xetra
11:35:54 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 376.45 EUR | +0.95% |
|
+5.71% | +34.30% |
| 08-21 | FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case | DJ |
| 08-20 | Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1,119B | |||||
| 651B | - | - | - | ||
| 468B | |||||
| 374B | |||||
| 302B |
- Stock Market
- Stocks
- AMGN Stock
- AMG Stock
- Charts Amgen Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
